{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 9 of 74', '4 Trial Synopsis', 'Title of clinical trial', 'INTERIM: a randomised phase II feasibility', 'study of INTERmittent versus continuous', 'dosing of oral targeted combination therapy', 'In patients with BRAFV600 mutant stage 3', 'unresectable or Metastatic melanoma', 'Sponsor name', 'Cambridge University Hospitals NHS', 'Foundation Trust', 'EudraCT number', '2016-005228-27', 'Medical condition or disease', 'BRAFV600 mutant stage 3 unresectable or', 'under investigation', 'metastatic melanoma', 'Purpose of clinical trial', 'To investigate continuous versus intermittent', 'dosing of dabrafenib plus trametinib in', 'patients with BRAFV600 mutant stage 3', 'unresectable or metastatic melanoma', 'Primary objectives', 'To assess recruitment rate and treatment', 'compliance of the intermittent dosing', 'schedule as a measure of acceptance of', 'intermittent dosing to patients and', 'physicians;', 'To evaluate the impact on Overall quality', 'of life (QoL) with intermittent dosing using', 'European Organisation for Research and', 'Treatment of Cancer (EORTC) QLQ-C30;', 'To estimate the size of clinical efficacy of', 'intermittent dosing compared to', 'continuous dosing, measured by', 'progression-free survival (PFS).', 'Secondary objectives', 'To evaluate safety, objective response', 'rate, time to treatment failure and overall', 'survival', 'To evaluate skin toxicity as assessed by', 'clinicans and patients using patient', 'reported outcome measures (PROMS)', '(Skindex-16 and patient-reported', 'outcomes version of the CTCAE (PRO-', 'CTCAE))', \"To assess factors which influence patients'\", 'decision to enter/decline entering the trial', 'To evaluate patient experience of', 'participation in this trial (using mixed', 'methods)', 'To determine the QoL and cost-', 'effectiveness of intermittent dosing', 'compared with standard continuous dosing', 'Exploratory objectives', 'To explore emergence of resistance by', 'means of circulating tumour DNA (ctDNA)', 'collected from patients during the course', 'of their treatment', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 10 of 74', 'To determine the role of ctDNA as a useful', 'biomarker for therapeutic monitoring', 'In a subset of patients (up to 20), explore', 'pharmacokinetics of standard versus', 'intermittent dosing schedules', 'Trial Design', 'INTERIM is a multi-centre, open label, two-', 'arm, randomised phase II feasibility trial.', 'Trial Outcome Endpoints', 'Primary endpoints:', 'Recruitment rate', 'Treatment compliance', 'Overall QoL (global health status)', 'PFS', 'Secondary endpoints:', 'Safety', 'Objective response rate', 'Time to treatment failure', 'Overall survival (OS)', 'Patient reported outcomes', 'focussing on skin toxicity', 'Patient experience consent and', 'treatment', 'QoL and Health Economic', 'Evaluation', 'Exploratory endpoints:', 'Predictive biomarkers', 'Pharmacokinetics', 'Sample Size', '150 patients', 'Summary of inclusion criteria', 'Main inclusion criteria:', 'Signed informed consent', 'Age 18 years old', 'Histologically or cytologically', 'confirmed BRAFV600 mutant stage 3', 'unresectable or metastatic melanoma', 'Measurable disease by Response', 'Evaluation Criteria In Solid Tumors', '(RECIST V1.1)', 'Eastern Cooperative Oncology Group', '(ECOG) performance status 0-2', 'Minimum life expectancy 12 weeks', 'Adequate bone marrow, renal and liver', 'function', 'Received no prior BRAF or MEK', 'inhibitor therapy for metastatic disease', 'Willing and able to comply with the', 'scheduled visits, treatment plans,', 'laboratory tests, completion of QoL', 'questionnaires and other trial', 'procedures', 'Archival tumour tissue sample', 'available', 'Summary of exclusion criteria', 'Main exclusion criteria:', 'Concomitant immunotherapy', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}